Home / Biotechnology / Hospital A

Hospital Acquired Disease Testing Market by Infection Type (Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, MRSA) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Hospital acquired infections (HAI) or diseases, also called as nosocomial infections are acquired in healthcare in-patient settings. It is estimated that in the U.S., 9.2 out of every 100 parents acquire hospital infection. Urinary tract infection and pneumonia are the most common types of HAI, followed by bloodstream infection, and surgical site infection. These infections are caused by pathogens, among patients with compromised immunity. Patients may also develop HAIs due to sub-standard healthcare settings and negligence on the part of hospital staff. The mortality and morbidity of HAIs and the associated costs has urged caregivers for devising efficient infection control strategies. Accurate and in-time diagnosis of HAIs are vital for efficient control and management of HAI.

The global hospital acquired disease testing market report studies this market in terms of major types of HAIs. These include hospital acquired pneumonia, urinary tract infection, bloodstream infection, surgical site infection, Methicillin-resistant Staphylococcus aureus (MRSA) and others. This report studies these segments in terms of their historical and future market size and forecast for the period 2014-2022. Respective compounded annual growth rates (CAGR %) for these segments for the period 2016-2022 are also presented in this study.

Geographically, the global hospital acquired disease testing market is studied for the following regional markets:

North America

a)       U.S.

b)       Canada

Europe

c)       U.K.

d)       Germany

e)       Rest of Europe

Asia-Pacific

f)        Japan

g)       China

h)       Rest of Asia-Pacific

Middle East and Africa

Latin America

The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 are also provided in this report.

Qualitative information such as drivers, challenges and future prospects for the global hospital acquired disease testing market are included in this report. Competition assessment tools such as fractal map analysis and attractive investment proposition are presented in this study for scrutinizing competition of the global hospital acquired disease testing market. This study concludes with company profiles section that highlights information about the key companies engaged in development, manufacture and provision of hospital acquired disease testing products.

Based on geographical segmentation, the global hospital acquired disease testing market is studied for:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Hospital Acquired Disease Testing Market

The regional classification is further elucidated as follows:

  • North America (U.S. & Canada)
  • Europe (U.K., Germany and Rest of Europe)
  • Asia-Pacific (Japan, China and Rest of Asia-Pacific)
  • Middle East and Africa
  • Latin America

North America is the largest market for hospital acquired disease testing, due to multitude of hospital admissions, and the growing need for containment of rising morbidity. Stringent guidelines for infection reduction and thus culminating the risk of readmission in hospitals have urged the emerging markets to grow at a rapid CAGR during the forecast period.

Choose License Type
Published Date:  May 2016
Category:  Biotechnology
Report ID:   57814
Report Format:   PDF
Pages:   120
Rating:    4.3 (55)
Connect With Us
+1-408-641-3282
24/7 Research Support